- Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, JunGuo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, JiuweiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)Liu, S. Y. M.; Zhou, Q.; Lu, C.; Deng, J. Y.; Wang, Z.; Li, Y. S.; Zheng, M. M.; Xu, B. F.; Dong, X. R.; Du, Y. Y.; Cui, J. W.; Chu, Q.; Bai, X. Y.; Sun, Y. L.; Li, A.; Xu, C-R.; Wang, B. C.; Chen, H. J.; Yang, J. J.; Wu, Y. L.
- Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal MetastasesZheng, Mei-Mei; Li, Yang-Si; Sun, Hao; Wu, Yi-Long*Journal of Thoracic Oncology, 2021, 16(2): E12-E14.被引 1
会议论文
High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
10阅读
